Clinical trials: Duodenal Adenocarcinoma
Esophageal Adenocarcinoma, Barrett's Esophagus
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome
- Conditions
- Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
- Trial name
- Mouthwash (NCT02513784)
- Testing
- Chlorhexidine gluconate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Columbia University
Pancreatic Adenocarcinoma
Pancreatic Juice Diagnosis From Duodenum
Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.
- Trial name
- NCT01699698
- Testing
- Tumor markers
- Where
- 2 sites in United States, Japan
- Volunteers
- 105 people
- Sponsor
- Olympus Corporation
Pancreatic Cancer
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and…
- Trial name
- NCT00766636
- Testing
- Gemcitabine, Radiation Therapy, Erlotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)